Objective. To investigate the effect of camrelizumab + apatinib combined with radiotherapy on the expression of TRIM27, SCC-Ag, and CYFRA21-1 in advanced oligometastatic non-small-cell lung cancer (NSCLC). Methods. A retrospective analysis of patients with oligometastatic NSCLC who were treated at our hospital from January 1, 2021, to March 31, 2022. Patients who met the inclusion criteria were summarized into an observation group (camrelizumab on the basis of the control group), or a control group (radiotherapy combined with oral apatinib). The disease control rate, immune function, changes in the levels of TRIM27, SCC-Ag, CYFRA21-1, and the occurrence of adverse effects were compared between the two groups. Result. There were 86 patients who met the inclusion criteria, with 53 cases in the observation group and 33 cases in the control group. There were significant differences in complete remission (CR, 25/53 vs. 10/33), partial remission (PR, 17/53 vs. 12/33), disease control (DC, 7/53 vs. 4/33), disease progression (DP, 4/53 vs. 7/33), and disease control rate (49/53 vs. 26/33) between the observation group and the control group. There was no significant difference in immune function between the two groups before treatment ( p > 0.05 ). After treatment, the levels of CD3+, CD4+, CD4+/CD8+t cells, and NK cells in the observation group were higher ( p = 0.015 , 0.035, 0.003, 0.001, respectively), while the level of CD8+t cells was lower ( p < 0.001 ). There were no significant differences in TRIM27, SCC-Ag, or CYFRA21-1 between the two groups before treatment ( p > 0.05 ). After treatment, the observation group had lower levels of TRIM27 ( p = 0.035 ), SCC-Ag ( p = 0.045 ), and CYFRA21-1 ( p = 0.003 ). There was no significant difference in the occurrence of adverse events between the two groups ( p < 0.05 ). Conclusion. Treatment of camrelizumab + apatinib combined with radiotherapy is effective for advanced oligometastatic NSCLC, with mild adverse effects.
Purpose Colon cancer is one of the most common digestive tract malignancies. Studies have shown that neutrophils can interact with immune cells and immune factors to affect the prognosis of patients. Methods We first determined the infiltration level of neutrophils in tumors using CIBERSORT and identified key genes in the final risk model by Spearman correlation analysis and subsequent Cox analysis. The risk score of each patient was obtained by multiplying the Cox regression coefficient by the gene expression level, and patients were divided into two groups according to the median. Differences in OS and PFS were assessed by KM survival analysis, and model accuracy was validated in another independent dataset. Finally, the differences in immune infiltration and immunotherapy were evaluated by immunoassay. Results We established and validated a risk scoring model based on neutrophil-related genes in two independent datasets; the patients in the high-risk group had a poorer prognosis than those in the low-risk group. A new nomogram was constructed and validated by combining clinical characteristics and the risk score model to better predict patient OS and PFS. Immune analysis showed that patients in the high-risk group had immune cell infiltration level, immune checkpoint levels, and tumor mutational burden and were more likely to benefit from immunotherapy. Conclusion The low-risk group had relatively better OS and PFS than the high-risk group in the neutrophil-related gene-based risk model. Patients in the high-risk group presented higher immune infiltration levels and tumor mutational burden and thus may be more responsive to immunotherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.